Paradigm Medical Industries (OTCMKTS:PDMI) vs. PAVmed (NASDAQ:PAVM) Head-To-Head Contrast

PAVmed (NASDAQ:PAVM) and Paradigm Medical Industries (OTCMKTS:PDMI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for PAVmed and Paradigm Medical Industries, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1	1	1	0	2.00
Paradigm Medical Industries	0	0	0	0	0.00

PAVmed currently has a consensus price target of $17.00, indicating a potential upside of 5,437.46%. Given PAVmed’s stronger consensus rating and higher probable upside, equities analysts plainly believe PAVmed is more favorable than Paradigm Medical Industries.

Profitability

This table compares PAVmed and Paradigm Medical Industries’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PAVmed	10,672.42%	-754.98%	-19.87%
Paradigm Medical Industries	N/A	N/A	N/A

Insider and Institutional Ownership

19.9% of PAVmed shares are owned by institutional investors. 9.2% of PAVmed shares are owned by insiders. Comparatively, 11.1% of Paradigm Medical Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares PAVmed and Paradigm Medical Industries”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$2.99 million	3.05	$39.79 million	($0.57)	-0.54
Paradigm Medical Industries	N/A	N/A	N/A	N/A	N/A

PAVmed has higher revenue and earnings than Paradigm Medical Industries.

Summary

PAVmed beats Paradigm Medical Industries on 6 of the 9 factors compared between the two stocks.

About PAVmed

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

About Paradigm Medical Industries

Paradigm Medical Industries, Inc. develops, manufactures, sells, and markets medical devices for the early detection of glaucoma and other eye disorders in the United States. The company offers P-2000 biometric analyzer A-scans and P-2500 A-scans/pachymeters; P2700 A/B and P37-II A/B scans; blood flow analyzers for the detection and management of glaucoma and other retinal vascular disorders; P2200 pachymeter and P-2500 A-scan/pachymeters; and LD 500 and LD700 autoperimeters. It also provides corneal topographers, such as PARAVUE 300 for diagnostic and contact lens applications, as well as SURVEYOR 500 for cornea and anterior segment; PARAMAX, which analyzes the functionality of ganglion cells and identifies glaucoma suspects; P60 and P60 ACI ultrasound biomicroscopes; and PARACAM 1000, a non-contact endothelial microscope, as well as software and accessories. The company was founded in 1989 and is based in Salt Lake City, Utah.